The invasion of placental trophoblast cells into the maternal decidua is an essential aspect of placental embedment. The process of placentation bears several striking similarities to tumor cell metastasis. However, trophoblastic migration during implantation and placentation is stringently controlled both in space and time. RhoGDI2 belongs to a family of Rho guanosine diphosphate dissociation inhibitors (RhoGDIs), and RhoGDI2 is a metastasis suppressor gene and a marker of aggressive human cancer. We evaluated whether RhoGDI2 has a physiological role in embryo implantation, particularly trophoblast migration. The mRNA and protein expression levels of RhoGDI2 were higher in term placentas compared with first-trimester placentas as detected by real-time PCR and Western blot. Immunohistochemical studies indicated that RhoGDI2 localized to the cytotrophoblast layer and extravillous trophoblast in firsttrimester placentas and was distributed in the syncytiotrophoblast layers of term placentas. Overexpression of RhoGDI2 in HTR-8/SVneo cells was associated with reduced RAC1-guanosine triphosphate (GTP) levels and inhibited cell migration. Conversely, small interfering RNA-mediated downregulation of RhoGDI2 resulted in significantly increased RAC1-GTP levels. Altered RhoGDI2 expression had no significant effects on cell proliferation. In conclusion, RhoGDI2 inhibits trophoblast cell migration, and this function may involve suppression of RAC1 activation.
INTRODUCTION
A successful pregnancy requires a coordinated program of decidualization, placentation, and embryo development. Embedment of the placenta is one of the most important steps [1] and involves the invasion of placental trophoblast cells into the maternal decidua. Placental trophoblasts undergo a complex process of proliferation, migration, and differentiation. Failures in this process can lead to clinical pathological conditions, including miscarriage [2] , intrauterine growth retardation [3] , preeclampsia [4] , and choriocarcinoma [5] .
The process of placentation bears a striking similarity to tumor cell metastasis. Characteristics of trophoblastic cells that resemble malignant cells include high proliferation rates, lack of cell contact inhibition, cell migration and invasion, and a capacity to escape effectors of the immune system [6] , particularly during the first trimester of pregnancy. However, unlike malignant migration, trophoblastic migration during implantation and placentation is stringently controlled in space and time.
RhoGDI2, also known as D4-GDI,RhoGDIB,Ly-GDI, belongs to a family of Rho guanosine diphosphate dissociation inhibitors (RhoGDIs) that include RhoGDI, RhoGDI2, and RhoGDI3 [7, 8] . The RhoGDIs control the cellular distribution of Rho guanosine triphosphatase (GTPase) and the interactions between Rho GTPases and regulatory guanine nucleotide exchange factors, GTPase-activating proteins, and effector targets involved in trafficking and cancer. Rho GTPase family proteins, including RHOA, RAC1, and CDC42, control signaling pathways that regulate a wide variety of biological processes such as cell cycle progression, migration, apoptosis, differentiation, senescence, gene expression, and vesicular trafficking [9, 10] . RhoGDI2 is preferentially expressed in hematopoietic cells [11] , but studies [12, 13] also have reported RhoGDI2 gene expression in nonhematopoietic neoplasms, including ovarian and bladder cancer cells. These findings suggest that RhoGDI2 may function in the progression of human tumors [14, 15] . RhoGDI2 is a known metastasis suppressor gene and a marker of aggressive human cancers [13] .
In light of these reports, we considered that RhoGDI2 might also have an important role in the placenta. We investigated the expression of RhoGDI2 in normal human first-trimester placentas and in term placentas. We also assessed the effects of RhoGDI2 on the migration of a human extravillous trophoblast (EVT) cell line, HTR-8/SVneo, in order to gain further insight into the biological and clinical importance of RhoGDI2 in human trophoblasts.
MATERIALS AND METHODS

Sample Collection
This study was approved by the ethics committee of Shengjing Hospital of China Medical University. The study was exempted from obtaining informed consent, but each patient's personal information was removed.
First-trimester placentas were collected anonymously from 14 healthy women undergoing elective termination of pregnancy between 6 and 10 postmenstrual wk of gestation for psychosocial reasons. Twenty term placentas were obtained from healthy pregnant women immediately following elective cesarean sections or vaginal delivery, in accordance with approved institutional ethics committee guidelines. Women being treated with nonsteroidal antiinflammatory drugs and those with a history of infection, chorioamnionitis, or asthma or undergoing induction of labor were excluded from the study. Tissue samples either were frozen immediately at À808C for subsequent RNA and protein analyses or were fixed in 4% paraformaldehyde at room temperature overnight for immunohistochemistry. 
Western Blot
Placental samples were homogenized on ice for 30 min in ristocetininduced platelet agglutination buffer (Beyotime Institute of Biotechnology).
Homogenates were centrifuged at 12 000 3 g, and supernatants were collected and stored at À808C. A protease inhibitor cocktail (Beyotime Institute of Biotechnology) was added to the samples to prevent protein degradation. Protein concentrations were determined using a bicinchonininc acid (BCA) protein assay kit (Beyotime Institute of Biotechnology). Proteins extracted from placental samples were electrophoretically separated by 0.1% SDS-PAGE (10% polyacrylamide) and were electrically transferred onto nitrocellulose membranes. After incubating for 1 h in blocking solution (5% [w/v] skim milk in Tris-buffered saline and tween 20 (TBS-T), the membranes were immunoblotted overnight with rabbit anti-RhoGDI2 (diluted 1:1000, product No. ab88317; Abcam). Blots then were rinsed three times with TBS-T for 45 min and were incubated with the appropriate anti-IgG (horseradish peroxidase [HRP]-linked anti-rabbit IgG) for RhoGDI2 (diluted 1:5000 in TBS-T) for 2 h. Blots were washed three additional times with TBS-T, and antibody-antigen complexes were detected using an enhanced chemiluminescence detection system (Syngene).
Immunohistochemistry
Placental samples were fixed at room temperature in 4% (v/v) paraformaldehyde for 24 h, dehydrated, and embedded in paraffin. Serial histological sections (4.0 lm thick) were deparaffinized in xylene, hydrated in graded alcohols, and immersed in PBS. Antigen retrieval was achieved by immersing the slides in 10 mM citrate buffer and boiling in a microwave oven for 10 min. Slides then were rinsed three times in PBS. After antigen retrieval, sections were incubated in an aqueous solution of 3% hydrogen peroxide for 20 min at 378C. The slides then were rinsed an additional three times in PBS. After blocking nonspecific binding with 5% nonfat milk, slides were incubated with polyclonal rabbit anti-human RhoGDI2 antibodies (diluted 1:500) overnight at 48C and then were treated with peroxidase-conjugated streptavidin (Beyotime Institute of Biotechnology) for 30 min at room temperature. Slides were rinsed in PBS, and immunoreactive proteins were visualized after the addition of diaminobenzidine (Beyotime Institute of Biotechnology) for 1 min. Slides were counterstained with hematoxylin for 3 min. Slides then were rinsed with water, dehydrated in graded alcohols, transferred to xylene, and mounted with nonaqueous mounting medium and coverslips. As negative controls, normal IgG was used in place of the primary antibodies.
EVT Cell Line and Culture
The immortalized first-trimester EVT cell line, HTR-8/SVneo [16] , derived from the short-lived primary EVT cell line, HTR-8, was generously provided by Dr. Charles H. Graham (Department of Anatomy & Cell Biology, Queen's University at Kingston, Canada) for use in the present study. Unless specified otherwise, HTR-8/SVneo cells were cultured in RPMI 1640 medium (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gibco) and 2% penicillinstreptomycin (Beyotime Institute of Biotechnology) in a sterile incubator at 378C with 95% humidity and 5% carbon dioxide. Before experiments, cells were washed with serum-free medium.
Plasmid Transfection
Full-length RhoGDI2 was cloned into a pIRES2-EGFP vector (Invitrogen). The pIRES2-EGFP-RhoGDI2 or empty vector was transfected into cells using Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer's recommendations. Transfected cells were assayed by Western blot at 48 h after transfection for the upregulation of RhoGDI2. 
Small Interfering RNA Preparation and Transfection
Transwell Migration Assay
The random migration of HTR-8/SVneo cells was evaluated using a previously reported protocol [17] with some modifications. The HTR-8/SVneo cells were resuspended in serum-free RPMI 1640 medium at 1 3 10 5 cells/ml, and 200 ll of cells was deposited on the top of a transwell insert. To the lower well, 600 ll of RPMI 1640 medium supplemented with 20% FBS was added. Cells were incubated at 378C in 5% carbon dioxide and were allowed to migrate for 48 h. Inserts then were washed twice with PBS, fixed with 4% paraformaldehyde, and stained using crystal violet. The upper surface of the filter was wiped with a cotton-tipped applicator to remove nonmigrated cells. The total number of cells on the underside of the insert was counted under a light microscope at 4003 magnification. The cell migration index (MI) was determined by counting the number of stained cells on the membrane in five randomly selected nonoverlapping fields at 4003 magnification under a light microscope. The researcher (H.C.) was blinded to experimental conditions. The MI was calculated as follows: (migrated cell numbers of agent-treated cells)/ (migrated cell numbers of nontreated cells). The numbers of migratory cells in the different treatment groups were plotted as relative changes with respect to controls. Data were obtained from three individual experiments.
Cell Growth Assays
Cell survival was determined using the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay described previously [18] with some modifications. Briefly, at 48 h after transfection, cells were seeded at a previously optimized density (5 3 10 3 cells per well) in 96-well plates. After 48 h in culture, 20 ll of MTT was added to each well, and cells were incubated for 4 h at 378C. Cells were lysed by the addition of 100 ll of dimethyl sulfoxide to each well, and lysates were incubated at 378C for 30 min. Absorbance was determined at 490 nm using a multidetection microplate reader (Bio-Tek Instruments). Each assay condition was performed in triplicate and was replicated five times within each experiment.
RAC1 Activation Assays
Detection of RAC1 GTPase activity was performed using a G-LISA kit (Cytoskeleton) according to the manufacturer's protocol. The HTR-8/SVneo cells were washed with PBS, resuspended in lysis buffer provided with the kit, and harvested from dishes using a cell scraper at 48 h after transfection. The concentration of total protein in each lysate was determined using the Precision RedTM advanced protein assay reagent provided with the kit. The G-LISA kit included a Rac1-GTP-binding protein immobilized on a plate. Bound active Rac1 was detected with a specific antibody and HRP detection reagent. The luminescence signal was quantified at 490 nm using a multidetection LIU ET AL. microplate reader (Bio-Tek Instruments). Each assay condition was performed in triplicate and replicated three times within each experiment.
Statistical Analysis
All statistical analyses were performed using SPSS 17.0 software (SPSS Inc.). Quantitative data are presented as means 6 SDs. Comparisons of two groups were performed using either the Student t-test (for parametric data) or the Mann-Whitney U-test (for nonparametric data). When data sets contained more than two groups, statistical significance was evaluated using ANOVA, followed by post hoc tests or Kruskal-Wallis H-test (for nonparametric data). P , 0.05 was considered significant.
RESULTS
Expression of RhoGDI2 in Human Placenta
Among term human placentas, Dcycle threshold value (Ct) values for RhoGDI2 ranged from 1.732 to 2.579, whereas DCt values for RhoGDI2 in first-trimester placentas ranged from 3.145 to 4.744. Among term human placentas, RhoGDI2 mRNA levels were almost 3-fold higher than RhoGDI2 mRNA levels from first-trimester placentas (P , 0.05) (Fig. 1A) .
Western blot confirmed the presence of RhoGDI2 in solubilized protein extracts from placental tissues and indicated strong placental expression of RhoGDI2 protein. The RhoG-DI2 protein levels in term placental tissues were 6-fold higher than those of first-trimester placental samples (P , 0.05) (Fig.  1B) .
The spatial and temporal expression patterns of RhoGDI2 protein in first-trimester and term placentas were determined by immunohistochemistry. Among first-trimester placentas, immunohistochemical analysis of RhoGDI2 protein indicated expression in cytotrophoblasts and EVTs, with higher expression in cytotrophoblasts than the invasive EVTs and with weaker staining in the mesenchyme (Fig. 2, A and C) . In placentas at term, positive immunoreactivity for RhoGDI2 was observed in syncytiotrophoblast layers, and RhoGDI2 expression was observably increased in the term syncytiotrophoblast (Fig. 2E) . Control sections using normal IgG in place of primary antibodies or omitting secondary antibodies showed no specific staining (Fig. 2, B, D, and F) .
RhoGDI2 Is Expressed in Human HTR-8/SVneo Cells
To examine the involvement of RhoGDI2 in trophoblast function in vitro, we first verified that HTR-8/SVneo cells express RhoGDI2 mRNA (Fig. 3A) and protein (Fig. 3B) . The RT-PCR results showed a specific 342-bp band corresponding to RhoGDI2. Immunostaining of HTR-8/SVneo cells indicated the presence of RhoGDI2 protein in the nuclear and cytoplasmic compartments (Fig. 3B ).
Overexpression and Knockdown of RhoGDI2 in HTR-8/ SVneo Cells
At 48 h after transfection, we examined RhoGDI2 protein expression by Western blot. Transfection with RhoGDI2 siRNA (siRhoGDI2) significantly reduced RhoGDI2 protein levels (Fig. 4) , whereas transfection with RhoGDI2 plasmid significantly increased RhoGDI2 protein levels compared with nontransfected HTR-8/SVneo cells (P , 0.05).
Effect of RhoGDI2 on Migration of HTR-8/SVneo Cells
A low level of RhoGDI2 in early trophoblasts implies a role for RhoGDI2 in the high invasiveness of EVT cells during early pregnancy. We therefore examined whether RhoGDI2 affected the migration of HTR-8/SVneo cells by overexpression and knockdown of RhoGDI2. Overexpression of RhoG-DI2 markedly inhibited the migration of HTR-8/SVneo cells to 64.7% 6 4.0% of controls (P , 0.05) (Fig. 5) . In contrast, knockdown of RhoGDI2 increased the migration of HTR-8/ SVneo cells to 131.4% 6 5.3% of controls (P , 0.05). We observed no significant differences among empty vector, control, and scrambled siRNA cells (Fig. 5) .
Effect of RhoGDI2 on Proliferation of HTR-8/SVneo Cells
We assessed the effect of RhoGDI2 on cell proliferation using the MTT proliferation assay. Overexpression or knockdown of RhoGDI2 had no significant effects on cell proliferation after 48 h in culture (Fig. 5G) . These findings confirmed that the changes in cell numbers resulting from migration were not caused by cell proliferation.
RhoGDI2 Inhibits the Activation of RAC1
Knockdown of siRhoGDI2 in HTR-8/SVneo cells induced the activation of RAC1 as detected by G-LISA. In contrast, RhoGDI2 overexpression inhibited the activation of RAC1, suggesting that RhoGDI2 inhibits RAC1 (Fig. 6 ).
DISCUSSION
We have described for the first time to date the expression and localization of RhoGDI2 in first-trimester and term human placentas using PCR techniques and antibody labeling. Our RhoGDI2 AND HUMAN TROPHOBLAST MIGRATION data indicate that RhoGDI2 is present in first-trimester and term human placentas.
RhoGDI2 is preferentially expressed in hematopoietic cells. However, Theodorescu et al. [15] reported that RhoGDI2 expression in normal human tissues is not limited to the hematopoietic compartment. Specifically, strong RhoGDI2 protein expression was detected in normal white blood cells, endothelial cells, and transitional epithelium, including the placenta. However, the study did not examine the spatiotemporal expression of RhoGDI2 in the placenta.
Dokras et al. [19] reported that cytotrophoblasts isolated from third-trimester placental tissues have the lowest invasive capacity in in vitro invasion experiments compared with cytotrophoblasts isolated from first trimesters. We characterized the expression and localization of RhoGDI2 in the present study. We detected localization of RhoGDI2 to cytotrophoblasts coupled with low mRNA and protein expression in firsttrimester placental tissues when decidual invasion is maximal. We also demonstrated that RhoGDI2 expression is high in nonmotile villous cytotrophoblasts but low in invasive EVT, suggesting that RhoGDI2 has a key role in regulating trophoblast migration. Notably, this process shares some similarities with tumor cell invasion but is finite and stringently regulated in space and time.
Several studies have described functional roles for RhoG-DI2 in breast, ovarian, gastric, and bladder cancers and in Hodgkin lymphoma. Zhang and Zhang [20] reported that knockdown of RhoGDI2 expression in MDA-MB-231 cells blocked cell motility and invasion. RhoGDI2 antagonized the invasive and metastatic phenotypes of HeyA8 ovarian cancer cells [21] . In 2009, Cho et al. [22] reported that RhoGDI2 could function as a positive regulator for the malignant RhoGDI2 AND HUMAN TROPHOBLAST MIGRATION progression of gastric cancer. The forced expression of RhoGDI2 in highly aggressive T24T bladder cancer cells suppressed cancer cell invasion and motility [13] . Ma et al. [23] reported that virtually all Hodgkin and Reed-Sternberg cells in classical Hodgkin lymphoma lacked RhoGDI2 protein expression. Taken together, these reports suggest that RhoGDI2 has opposing roles in aggressive tumor behavior, depending on tumor types and the cellular microenvironment.
Our findings support that RhoGDI2 may be involved in human trophoblast cell migration via inhibition of RAC1 activation. Specifically, overexpression of RhoGDI2 significantly inhibited the migration of HTR-8/SVneo cells in the migration assays. In addition, RhoGDI2 overexpression significantly downregulated the expression of RAC1 activation protein, which functions in trophoblast cell migration.
Several studies have indicated that phosphorylation of the transcription factor c-June and RAC1 activity were significantly lower in the placentas of women with preeclampsia or HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count) compared with controls [24] , suggesting a potential contribution of Rac1 to placental development. RAC1 has been shown to stimulate the activities of matrix metalloproteinase 2 (MMP2) [25] and MMP9, which have important roles in trophoblast invasion, possibly via mitogen-activated protein kinase 8, which also is known as the Jun N-terminal kinase-dependent pathway [26] . Nicola et al. [27] reported that RAC1 reduced prostaglandin E 2 -dependent migration of HTR-8/SVneo cells and trophoblasts in villous explant cultures. Saso et al. [28] suggested that RHO kinase, RAC1, and RHOC are essential for insulin-like growth factor binding protein 1-induced EVT migration and that RHOA and CDC42 are not essential. These studies suggest that Rac1 may control the migratory abilities of trophoblast cells. Our data indicate that RhoGDI2 inhibited cell migration by suppressing the activation of RAC1, whereas a RhoGDI2 deficiency induced an upregulation of Rac1 and enhanced cell migration.
In conclusion, this is the first report to date to describe the localization and potential function of RhoGDI2 in human placental tissues, with a particular focus on EVT. RhoGDI2 is expressed in EVT and may regulate the migration of HTR-8/ SVneo cells. Further studies are required to clarify the mechanisms underlying RhoGDI2 function in EVT.
